Seventure Partners

Anybuddy is a leading sports booking marketplace in France, specializing in racket sports. The company has developed a sports application that facilitates the discovery of players and venues for football and tennis matches. Its platform provides users with access to hundreds of clubs, allowing them to reserve and pay for bookings without the need for a license or subscription. By offering a variety of quality tennis courts and multiple play surfaces, Anybuddy enables users to make reservations directly through the application at competitive prices.

Syroco is a scientific and technical laboratory based in Marseille, France, focused on enhancing efficiency in the transportation and energy sectors. Established in 2019, the company specializes in innovative solutions, including the development of a speed craft aimed at breaking sailing speed records. Syroco was founded by a diverse team, including a kitesurfer, a two-time world sailing record holder, and experts from startup and naval architecture backgrounds. The company adopts a unique approach characterized by "moonshot challenges," which encourage technological advancements to address significant industry hurdles. Additionally, Syroco develops modeling software that utilizes data and artificial intelligence to create digital twins, thereby optimizing operational and energy efficiency within maritime transportation. This forward-thinking approach positions Syroco as a pivotal player in supporting the sustainable transition of energy sectors while engaging collaboratively with industry stakeholders.

Aenitis Technologies is a French start-up founded in July 2014 by researchers Mauricio Hoyos and Jean-Luc Aider from the CNRS. The company specializes in the development of innovative medical devices that address challenges in cell therapy preparation and bioprocessing. Aenitis Technologies focuses on solutions for cell sorting, washing, and isolation, utilizing acoustophoresis technologies to enhance the efficiency of these processes. With an emphasis on revolutionizing practices in public health, Aenitis Technologies aims to establish itself as a world leader in the separation and filtration of biological elements, providing vital support to cell therapy units and blood banks in the healthcare industry.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Nexess SAS is a French company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Established in 2006 and headquartered in Mougins, France, with an additional office in Paris, Nexess offers a comprehensive range of products, including the NexLink software platform, which enhances security and productivity. The company also provides a variety of identification products such as personal security badges, RFID tags, and mobile devices, as well as smart camera systems that enable autonomous image analysis and real-time data transmission. Its solutions are designed for applications like hazardous product traceability, secure equipment management, site localization, and access detection in hazardous zones. Nexess aims to support digital transformation projects through its innovative technology, enhancing productivity, quality, and security for its clients.

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

Mediarithmics is a cloud-based marketing technology company headquartered in Fontenay-sous-Bois, France. Founded in 2011, it offers a next-generation customer data platform (CDP) that integrates data management and marketing automation functionalities. The platform allows brands to manage retargeting campaigns across multiple devices, including mobiles, tablets, and PCs, while enabling agencies to handle clients' real-time bidding (RTB) and email campaigns through a unified tool. Mediarithmics supports the creation of data alliances to ensure data security and compliance with regulations, facilitating the collection and segmentation of customer data for real-time, multi-channel campaign activation. Additionally, the platform allows clients to incorporate their own algorithms for enhanced personalization in marketing strategies, focusing on consumer engagement and effective measurement of campaign performance.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Hardloop is an online retailer based in Paris, France, specializing in sports products and adventure gear. Established in 2014, the company offers a diverse range of equipment and clothing for various outdoor activities, including hiking, trail running, skiing, climbing, and swimming. Through its platform, Hardloop provides sports enthusiasts with access to a wide selection of shoes, gloves, bottles, and other essential accessories from numerous international brands, catering to the needs of those seeking new adventures in sports.

SportEasy is a management platform designed for amateur sports teams, launched in France in 2011. The application facilitates the organization of games and practices, enabling coaches to effectively manage their teams and communicate with players. It includes features for capturing and analyzing statistics, as well as social tools that allow players to engage with one another, such as voting for the player of the game, participating in private forums, and sharing photos. Available on both web and mobile platforms, SportEasy supports users in French and English. While the core app is free, premium plans for teams and clubs were set to be introduced in early 2015. The platform aims to streamline administrative tasks, allowing coaches, managers, and players to focus more on the sport itself.

Expensya SAS is a Paris-based company specializing in multi-platform expense management software solutions. Founded in 2015, the company provides a web and mobile application designed to automate the entire process of expense report management, from receipt handling to archiving. The platform incorporates advanced technologies, including Cloud computing, Artificial Intelligence, and Machine Learning, to enhance efficiency and streamline workflows. Expensya's application is compatible with various devices, including Android, iOS, and Windows phones, and supports eight languages while adapting to local accounting regulations in approximately fifty countries. Its features include expense management, data export, accountant integration, approval workflows, and a statistics module, making it a comprehensive tool for businesses seeking to simplify and secure their expense reporting processes.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Hardloop is an online retailer based in Paris, France, specializing in sports products and adventure gear. Established in 2014, the company offers a diverse range of equipment and clothing for various outdoor activities, including hiking, trail running, skiing, climbing, and swimming. Through its platform, Hardloop provides sports enthusiasts with access to a wide selection of shoes, gloves, bottles, and other essential accessories from numerous international brands, catering to the needs of those seeking new adventures in sports.

TIBOT Technologies SAS, founded in May 2016 and located in Cesson-Sévigné, France, specializes in designing and developing robotic solutions for poultry farming. The company aims to enhance the daily operations of poultry farmers by providing innovative tools that improve animal welfare and profitability. Its key products include the Spoutnic, an assistant robot that helps with various tasks, and Spoutnic NAV, which autonomously scrapes, drinks, and feeds poultry. TIBOT Technologies focuses on reducing the incidence of eggs being laid on the ground, thereby increasing the hatching rate and improving both working conditions for farmers and the overall welfare of the animals. Through its technologies, TIBOT strives to simplify poultry farming practices and make them more efficient.

JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.

LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Expensya SAS is a Paris-based company specializing in multi-platform expense management software solutions. Founded in 2015, the company provides a web and mobile application designed to automate the entire process of expense report management, from receipt handling to archiving. The platform incorporates advanced technologies, including Cloud computing, Artificial Intelligence, and Machine Learning, to enhance efficiency and streamline workflows. Expensya's application is compatible with various devices, including Android, iOS, and Windows phones, and supports eight languages while adapting to local accounting regulations in approximately fifty countries. Its features include expense management, data export, accountant integration, approval workflows, and a statistics module, making it a comprehensive tool for businesses seeking to simplify and secure their expense reporting processes.

Presto Engineering, Inc. is a provider of outsourced development operations tailored for semiconductor and Internet of Things (IoT) device companies. Established in 2006 and headquartered in San Jose, California, the company delivers a comprehensive suite of services, including turnkey IoT components, radio-frequency (RF) and mixed-signal solutions, and various testing and analysis services. These services encompass product engineering, debugging, reliability testing, and failure analysis, aimed at enhancing product performance and minimizing risk. Presto Engineering also specializes in wafer fabrication, backend packaging, and supply chain solutions, supporting clients in the medical, automotive, industrial, and communication sectors. With additional offices in France, Thailand, and Taiwan, the company is positioned to facilitate rapid product development and help clients accelerate their time-to-market.

Launchmetrics is a marketing and analytics platform that specializes in serving the fashion, luxury, and beauty industries. Founded in 2006 and headquartered in New York, with additional operations in Paris, the company offers a suite of products designed to enhance brand performance and streamline marketing processes. Its offerings include Samples, Events, Contacts, Discover, and Influencers by Launchmetrics, which collectively assist brands in planning product launches and improving media performance. The company has established itself as a trusted technology provider, working with over 1,000 clients, including prominent names like Dior, Fendi, and NET-A-PORTER, as well as partners such as the British Fashion Council and Google. With a presence in eight markets and support in five languages, Launchmetrics aims to empower brands to create impactful and measurable consumer experiences, adapting to the rapidly changing digital landscape. The company was originally known as Fashion GPS, Inc. before rebranding in January 2016.

MDoloris Medical Systems SAS is a French company founded in 2010, specializing in the development and manufacture of medical devices aimed at monitoring and assessing patient pain. The company is known for its Analgesia Nociception Index (ANI) monitors, which provide a direct measurement of autonomic nervous system activity, and are particularly useful for non-communicating patients. These devices are employed in various settings, including general anesthesia, post-surgical care, intensive care units, obstetrics, and neonatal care. Additionally, MDoloris offers after-sales services to support its products. By enabling clinicians to better understand and manage patient pain, the company enhances the effectiveness of analgesic treatment and improves patient outcomes across multiple healthcare environments.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

Intento Design SA, founded in 2015 and based in Paris, France, specializes in developing software that enhances the efficiency of analog and mixed-signal integrated circuit development. The company's flagship product, ID-Xplore, automates the analog design process from hand analysis to simulation, significantly reducing the time required for circuit sizing. Intento Design also provides services such as methodology adoption, design collaboration, and technology migration. Their solutions are tailored for designers in various markets, including consumer electronics, Internet of Things, big data, military, and medical sectors. The company's innovative approach originated from research conducted at Laboratoire d’Informatique de Paris 6, resulting in a robust portfolio of intellectual property focused on accelerating the design cycle for complex systems-on-chips (SoCs).

TargEDys is a biotechnology company based in Rouen, France, established in 2011. The company focuses on developing innovative mechanisms that utilize hormone mimetic proteins associated with the gut microbiota to address eating disorders, including hyperphagia and anorexia. TargEDys' approach aims to regulate appetite and metabolic functions by leveraging naturally occurring bacterial proteins found in the gut. This technology is designed to help overweight individuals manage their eating behavior and restore appetite in populations such as the elderly or those suffering from cachexia or anorexia. Through its research and development efforts, TargEDys seeks to provide effective solutions for appetite modulation and the treatment of related metabolic diseases.

Business Table is the leader in corporate dining and corporate events, with more than 30,000 service providers, including 15,000 restaurants, 1,500 caterers and 14,000 hotels and locations across France. This innovative solution launched in 2012 allows companies, from large groups to SMEs, to streamline the management of meal costs through a simple, innovative and efficient booking, ordering and invoicing tool. To expand its service offering, Business Table has partnered with American Express, Concur, Edenred and AirPlus

Botfuel, established in 2016 and headquartered in Paris, France, specializes in a web-based platform and SDK for creating and deploying chatbots. It empowers individuals and businesses to engage with customers on popular messaging channels, providing automated, personalized support and enhancing brand engagement. The platform leverages AI to develop modular, scalable chatbots, aiming to improve customer support and drive sales.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

TargEDys is a biotechnology company based in Rouen, France, established in 2011. The company focuses on developing innovative mechanisms that utilize hormone mimetic proteins associated with the gut microbiota to address eating disorders, including hyperphagia and anorexia. TargEDys' approach aims to regulate appetite and metabolic functions by leveraging naturally occurring bacterial proteins found in the gut. This technology is designed to help overweight individuals manage their eating behavior and restore appetite in populations such as the elderly or those suffering from cachexia or anorexia. Through its research and development efforts, TargEDys seeks to provide effective solutions for appetite modulation and the treatment of related metabolic diseases.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

MilliDrop Instruments SAS is a Paris-based company that specializes in the design and development of advanced cell culture machines utilizing millifluidics technology for bacteriological research and diagnostics. Established in 2015, MilliDrop focuses on creating innovative in vitro diagnostics instruments, such as the MilliDrop DIV, which facilitate the identification of infectious agents and the determination of appropriate antibiotic dosages. These instruments allow for the incubation, analysis, and manipulation of microscopic samples ranging from approximately 100 nanoliters to a few picoliters in volume. By enabling microbiologists to simultaneously study various cultures, monitor phenotypic diversity, and conduct serial dilutions, MilliDrop enhances the efficiency and accuracy of antimicrobial susceptibility testing across a range of microorganisms, including bacteria, fungi, and yeasts.

HorseCom SAS is a French company based in Caen, established in 2015, that specializes in developing innovative Bluetooth audio headset technology for horses and riders. The company aims to enhance the well-being, performance, and connection between horses and their riders through its patented audio products. HorseCom's offerings include a wearable device designed specifically for equine ears, which diffuses music to both horse and rider, promoting synchronization during training and enhancing the overall riding experience. This technology not only improves the horse's well-being but also aids in recovery and reduces stress in challenging situations. Additionally, the company provides a mobile application to complement its audio kits, which consist of Bluetooth earpieces for riders, a cap with a Bluetooth receiver, and earphones for horses, all aimed at building effective training programs in equestrian sports.

Intento Design SA, founded in 2015 and based in Paris, France, specializes in developing software that enhances the efficiency of analog and mixed-signal integrated circuit development. The company's flagship product, ID-Xplore, automates the analog design process from hand analysis to simulation, significantly reducing the time required for circuit sizing. Intento Design also provides services such as methodology adoption, design collaboration, and technology migration. Their solutions are tailored for designers in various markets, including consumer electronics, Internet of Things, big data, military, and medical sectors. The company's innovative approach originated from research conducted at Laboratoire d’Informatique de Paris 6, resulting in a robust portfolio of intellectual property focused on accelerating the design cycle for complex systems-on-chips (SoCs).

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Mailjet is a comprehensive email service provider founded in France in 2010. It specializes in delivering marketing and transactional emails, serving over 26,000 clients in 156 countries and facilitating the transmission of nearly 1 billion emails each month. The company offers a real-time cloud emailing platform that enables clients to send, track, and optimize their email communications effectively. Mailjet's proprietary technology includes advanced analytics tools and intelligent APIs, along with features like A/B testing and Campaign Comparison, which enhance email performance. Additionally, the company provides consulting services to ensure optimal deliverability, supported by a multilingual customer service team available around the clock.

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

Augure is a software company founded in 2002 in Paris, specializing in influencer marketing and public relations solutions. The company offers a platform that assists brands and agencies in managing their communication strategies by bridging the gap between traditional PR and influencer marketing. With over 1,000 clients utilizing the platform daily, Augure enables communication, PR, and public affairs teams to engage with relevant influencers, streamline campaign management, and enhance their media presence on social networks. In addition to its software, Augure provides consulting services through its data services team, helping clients interpret and leverage data to optimize their influencer marketing strategies. The company operates primarily in Europe and Latin America, serving a diverse range of clients, including prominent organizations in the corporate sector.

Aenitis Technologies is a French start-up founded in July 2014 by researchers Mauricio Hoyos and Jean-Luc Aider from the CNRS. The company specializes in the development of innovative medical devices that address challenges in cell therapy preparation and bioprocessing. Aenitis Technologies focuses on solutions for cell sorting, washing, and isolation, utilizing acoustophoresis technologies to enhance the efficiency of these processes. With an emphasis on revolutionizing practices in public health, Aenitis Technologies aims to establish itself as a world leader in the separation and filtration of biological elements, providing vital support to cell therapy units and blood banks in the healthcare industry.

Open Ocean SAS is a French company, established in 2011 and operating out of Brest and Paris, that specializes in developing SaaS-based decision-making platforms for offshore infrastructure and marine operations. The company offers a range of innovative solutions, including the Metocean Analytics tool, which analyzes atmospheric and oceanic conditions, and provides comprehensive reports on tidal energy markets in France. Additionally, Open Ocean produces a spectral wave database to support the development of marine renewable energy in Scotland. Their services include site data analysis, resource and energy assessment, environmental impact assessments, and adherence to greenhouse gas protocols for wave and tidal energy projects. Open Ocean's highly qualified team of oceanographers, trained at leading research institutions, focuses on high-resolution modeling, statistical analysis, and data mining, catering to farm developers, operators, and public agencies in the renewable marine energy sector. As of September 2019, Open Ocean operates as a subsidiary of Artelia SAS.

JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Webinterpret, established in 2007, focuses on making international e-commerce accessible to sellers worldwide. With offices in France, Poland, China, and the USA, the company employs approximately 210 skilled e-commerce specialists who possess in-depth local market knowledge. Webinterpret operates a global marketplace platform designed to help online merchants expand their reach internationally. The platform offers a range of services, including adjustments to shipping costs, currency conversion, product categorization, accurate translations, and international stock management. These services enable online retailers and marketplace sellers to effectively grow their businesses on a global scale and enhance their online sales.

Streamdata.io is a software developer specializing in API management, focusing on real-time caching and event-driven infrastructure. Established in 2008 and headquartered in Meylan, France, the company provides a range of services through three main offerings: Distribute, Journey, and Discover. Distribute enables businesses to consume and publish events alongside APIs, transforming traditional request/response models into dynamic event streams. Journey offers consulting and tools to enhance the API lifecycle, while Discover assists companies in cataloging their digital assets to create high-quality APIs. Streamdata.io employs machine-learning techniques to optimize API bandwidth usage across various platforms, including web, mobile, and IoT, allowing developers to enhance user experiences and mitigate server load. The company has received several accolades, including the European Data Award at Vivatech and recognition as a top startup in various competitions. As a subsidiary of Axway Software SA, Streamdata.io actively contributes to industry standards such as AsynchAPI and OpenAPI.

Global Bioenergies SA specializes in developing a biological process that converts renewable resources into isobutene, a crucial petrochemical building block used in fuels, plastics, organic glass, and elastomers. The company, based in Evry, France, is notable for being one of the few globally and the only one in Europe focusing on this innovative fermentation technology. It operates an industrial pilot plant and is nearing the completion of a demonstration plant in Germany, alongside preparing for its first full-scale production facility in collaboration with Cristal Union, known as IBN-One. In addition to isobutene, Global Bioenergies has expanded its capabilities to include the production of propylene and butadiene, both vital components in the petrochemical sector. The company was founded in 2008 and continues to enhance the efficiency of its processes while offering engineering services related to gas fermentation.

Advanced Accelerator Applications S.A., founded in 2002 and based in Saint Genis Pouilly, France, specializes in the development, production, and commercialization of molecular nuclear medicine products for diagnostic and therapeutic purposes. The company offers a range of products including oxodotreotides, dotatate injections, edotreotide solutions, flurochol, and gluscan, which are used in oncology, cardiology, and neurology. Additionally, it provides innovative solutions like LysaKare for reducing kidney radiation exposure during therapy, DOPAVIEW for rapid tissue accumulation, CARDIOGEN for producing rubidium chloride, NEUROLITE for radiopharmaceutical preparation, LUMARK as a radiopharmaceutical precursor, and LEUKOKIT for leukocyte separation and labeling. The company's theragnostic platform uses radiolabeling to target tumor cells, aiding in diagnosis, monitoring, and staging. Advanced Accelerator Applications operates as a subsidiary of Novartis AG.

Nexess SAS is a French company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Established in 2006 and headquartered in Mougins, France, with an additional office in Paris, Nexess offers a comprehensive range of products, including the NexLink software platform, which enhances security and productivity. The company also provides a variety of identification products such as personal security badges, RFID tags, and mobile devices, as well as smart camera systems that enable autonomous image analysis and real-time data transmission. Its solutions are designed for applications like hazardous product traceability, secure equipment management, site localization, and access detection in hazardous zones. Nexess aims to support digital transformation projects through its innovative technology, enhancing productivity, quality, and security for its clients.

Recommerce Group specializes in the trade-in, refurbishment, and remarketing of second-hand smartphones across Europe. Founded in 2009 and headquartered in Paris, France, the company employs advanced proprietary technologies to give a second life to mobile devices, offering a wide array of premium quality products under its own brand. Recommerce Group provides comprehensive solutions that include buyback services, real-time market pricing, and leasing programs, facilitating affordable access to refurbished electronics. The company serves a diverse clientele, including mobile network operators, distributors, e-tailers, and manufacturers, through both online and physical distribution channels in France, Switzerland, Spain, and beyond. Additionally, Recommerce Group offers marketing and logistical support, as well as customer services, ensuring a seamless experience for its partners and customers alike.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.

Web Geo Services SAS, founded in 2009 and headquartered in Montpellier, France, specializes in online mapping and geolocation technology tailored for various sectors, including retail, e-commerce, travel, banking, and automotive. The company empowers businesses to utilize Google Maps effectively, enhancing customer engagement and driving conversions. As a strategic partner of Google Cloud and recognized as the leading Google Maps partner in Europe, Web Geo Services supports over 400 large enterprises in rapidly deploying digital systems that optimize online checkout and customer journeys. Their flagship platform, Woosmap, offers developers robust Location Intelligence features for mobile apps and websites. Furthermore, Web Geo Services develops cloud-based geolocation solutions that facilitate community engagement and streamline operational processes for businesses, ultimately helping clients boost their revenue through innovative location-based services.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

ProTip SA is a privately held medical device company dedicated to the development of innovative solutions for patients suffering from larynx malfunctions. Its priority focus is to develop a permanent implant for laryngectomized patients. ProTip, based in Strasbourg (Eastern France), was founded in 2004 and has since benefited from strong support from the Alsace region and Oseo, the French public agency for innovation. The company has won several prestigious awards in France. It has established partnerships with a number of academic institutions. The international expansion of the company has recently accelerated due to the ISO certification and CE mark achievement on essential product lines.

LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Streamdata.io is a software developer specializing in API management, focusing on real-time caching and event-driven infrastructure. Established in 2008 and headquartered in Meylan, France, the company provides a range of services through three main offerings: Distribute, Journey, and Discover. Distribute enables businesses to consume and publish events alongside APIs, transforming traditional request/response models into dynamic event streams. Journey offers consulting and tools to enhance the API lifecycle, while Discover assists companies in cataloging their digital assets to create high-quality APIs. Streamdata.io employs machine-learning techniques to optimize API bandwidth usage across various platforms, including web, mobile, and IoT, allowing developers to enhance user experiences and mitigate server load. The company has received several accolades, including the European Data Award at Vivatech and recognition as a top startup in various competitions. As a subsidiary of Axway Software SA, Streamdata.io actively contributes to industry standards such as AsynchAPI and OpenAPI.

Impeto Medical SAS is a privately owned medical device company established in June 2005, with its headquarters located in Paris, France, and additional subsidiaries in China and San Diego, California. The company specializes in the manufacture and marketing of non-invasive diagnostic devices that assess eccrine sweat gland activity. Its product lineup includes SUDOSCAN+, which is used for detecting and monitoring peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardio metabolic risks; and SUDOSCAN, a device that evaluates galvanic skin response to assess sympathetic nervous system behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical's innovative technology enables healthcare professionals to screen large patient populations effectively, facilitating early detection of metabolic disorders and related complications. The company distributes its products through a network of distributors.

Talentsoft, established in 2007, is a leading French software company specializing in cloud-based Talent Management solutions. It offers a comprehensive suite of services, including recruitment, onboarding, performance management, and learning management, all integrated on a single platform. Talentsoft has achieved rapid growth and international success by forming strategic partnerships, maintaining high-caliber teams, and providing an attractive technology solution. With numerous awards and financial backing, the company has expanded its global presence to every continent, serving clients through its network of subsidiaries and affiliates.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Arlettie, founded in 1993 and based in Paris, France, specializes in online retail of fashion apparel and accessories. The company operates as an intermediary between luxury and fashion brands and consumers, organizing private sales and exclusive shopping events. Through its platform, Arlettie offers a curated selection of luxury fashion, accessories, and lifestyle products from renowned brands, facilitating unique shopping experiences for discerning customers.

Efficity SAS is an online real estate agency located in Paris, France, established in 2007. The company specializes in providing a range of online real estate services, including the buying and selling of properties, property management, and property valuation. Efficity leverages digital platforms to facilitate real estate transactions, enabling clients to navigate the property market efficiently.

QuesCom S.A. is a company based in Sophia Antipolis, France, specializing in the design and manufacture of internet telecommunication systems. Founded in 1999, QuesCom develops a range of products including business communication management portals, GSM gateways, SIM servers, and mobile call servers. The company also offers VoIP technology and network management software, catering to the needs of enterprises and service providers. Through partnerships with leading telecommunications firms, QuesCom aims to enhance communication solutions and streamline business operations.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Presto Engineering, Inc. is a provider of outsourced development operations tailored for semiconductor and Internet of Things (IoT) device companies. Established in 2006 and headquartered in San Jose, California, the company delivers a comprehensive suite of services, including turnkey IoT components, radio-frequency (RF) and mixed-signal solutions, and various testing and analysis services. These services encompass product engineering, debugging, reliability testing, and failure analysis, aimed at enhancing product performance and minimizing risk. Presto Engineering also specializes in wafer fabrication, backend packaging, and supply chain solutions, supporting clients in the medical, automotive, industrial, and communication sectors. With additional offices in France, Thailand, and Taiwan, the company is positioned to facilitate rapid product development and help clients accelerate their time-to-market.

Talentsoft, established in 2007, is a leading French software company specializing in cloud-based Talent Management solutions. It offers a comprehensive suite of services, including recruitment, onboarding, performance management, and learning management, all integrated on a single platform. Talentsoft has achieved rapid growth and international success by forming strategic partnerships, maintaining high-caliber teams, and providing an attractive technology solution. With numerous awards and financial backing, the company has expanded its global presence to every continent, serving clients through its network of subsidiaries and affiliates.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

MLstate is a technology company focused on developing secure communications solutions and industrial web applications. It is well known for its proprietary product, Peps, which is designed to enhance secure digital communication. The company also created Opa, an advanced open-source framework for JavaScript, consisting of a compiler that features a JavaScript-like syntax with numerous improvements, alongside a runtime JavaScript library. MLstate's innovations have garnered recognition in the tech industry, including awards and publications, and the company has been a finalist in various prestigious competitions. MLstate's offerings facilitate email management, document collaboration, and file sharing within organizations, positioning the company as a key player in the development of web exchange platforms.

Webinterpret, established in 2007, focuses on making international e-commerce accessible to sellers worldwide. With offices in France, Poland, China, and the USA, the company employs approximately 210 skilled e-commerce specialists who possess in-depth local market knowledge. Webinterpret operates a global marketplace platform designed to help online merchants expand their reach internationally. The platform offers a range of services, including adjustments to shipping costs, currency conversion, product categorization, accurate translations, and international stock management. These services enable online retailers and marketplace sellers to effectively grow their businesses on a global scale and enhance their online sales.

CodaSystem is a French start-up that specializes in digital photography technology with legal value. The company provides a real-time monitoring tool that enables users to capture digital photographs using a mobile phone, which can then serve as legal evidence. This innovative software is designed to enhance the reliability and credibility of photographic documentation in various contexts, ensuring that users can easily generate legally admissible images.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

VoluBill S.A. is a provider of real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and based in Montbonnot Saint Martin, France, with additional offices in Europe and Asia, the company specializes in solutions for fixed, mobile, and fixed mobile convergent operators. VoluBill's product offerings include CHARGE-IT, which facilitates real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement; and CHARGE-IT Dynamic Charging Platform, which supports various charging models such as pre-pay, post-pay, and now-pay for data services.

Glowria offers online digital video disc (DVD) rental service. Glowria was founded in 2003 is based in Paris, France.

Idylis S.A., established in 2008 and headquartered in Issy-les-Moulineaux, France, specializes in designing, developing, and marketing software solutions tailored for enterprise management. The company's product suite supports a range of applications including audit and accounting, financial management, documentation, e-mailing, scheduling, supply chain management, logistics, and inventory management. Additionally, Idylis offers customer support and consulting services to enhance the effectiveness of its software solutions for clients.

Numara Software France SAS provides information technology (IT) and security management solutions. It offers Precision Desktop Management, an agent-based software designed to overcome IT management complexity; Precision Patch Management, an agent-based software designed to help IT managers to address and optimize the patch deployment process; and Precision Vulnerability Management, a non-intrusive vulnerability scanner. The company also provides services, such as IT asset management, vulnerability lifecycle management, software and configuration management, patch management, applications management, system monitoring, end user support, green IT-power management, OS deployment, and compliance. It serves bank, insurance, finance, distribution, education, government, health, industry, media, services, telecom/Internet, and TRANSPORT industries Antipolis and internationally. Criston SA was formerly known as Metrix Systems SA and changed its name to Criston SA in February 2004. The company was founded in 1997 and is headquartered in Sophia Antipolis, France with additional offices in Japan France, China, and Germany. As of July 13, 2009, Numara Software France SAS operates as a subsidiary of Numara Software, Inc.

DxO, established in 2002 and headquartered in Boulogne, France, specializes in the development and sale of digital image processing products and solutions. Its primary offerings include DxO Optics Pro, a software application for image correction and enhancement, and DxO FilmPack, which gives digital images the style of conventional films. Additionally, DxO licenses its intellectual property of optics and silicon architectures for embedded still and video image processing in camera phones and digital cameras. The company also provides DxO Analyzer, an image quality evaluation solution. DxO serves a diverse range of customers, from consumer electronics manufacturers to photographers and imaging experts, distributing its products through resellers and distributors.

METabolic EXplorer, founded in 1999 and headquartered in Saint-Beauzire, France, is a biochemistry company specializing in the development of industrial fermentation processes as sustainable alternatives to petrochemical methods. The company produces functional ingredients from natural origins for use in cosmetics, nutrition-animal health products, and biomaterials synthesis. By leveraging bacterial biochemistry, METabolic EXplorer aims to create viable, long-term solutions based on renewable resources, focusing on economic performance and competitiveness. The company continually works to enhance the efficiency of microorganisms and diversify the supply of renewable raw materials to produce essential chemical compounds with wide-ranging industrial applications.

AssurOne Group is a French company based in Asnières-sur-Seine, specializing in online insurance brokerage services since its founding in 2004. The firm provides a range of insurance products, including life, casualty, property, and automobile insurance, available through both the internet and telephone. AssurOne Group serves a diverse clientele, which includes notable names such as French Generali, AXA, and AG2R La Mondiale. The company operates a platform that facilitates insurance, registration, claims, and contract management services, allowing customers to access negotiated insurance contracts directly from providers without the need for brokers, ensuring competitive pricing. AssurOne Group operates as a subsidiary of Société Centrale Prévoyance SA.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor and electronic applications, focusing on damascene through silicon vias and MEMS. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, the company is based in Massy, France. Aveni's core offerings include Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been successfully implemented in manufacturing for processes at and below the 14 nm node and for high aspect ratios. Aveni collaborates with various research and development centers and leading global manufacturers, leveraging its expertise in surface science, chemistry, electrochemistry, and materials science to enhance device performance and yield in the semiconductor and renewable energy sectors.

Sefas Innovation, founded in 1991 and headquartered in Paris, France, specializes in collaborative document composition and production software, primarily catering to Fortune 500 companies. With additional offices in the UK and the US, the company employs over 80 staff members worldwide. Sefas' flagship product, the Open Print software suite, is utilized by various sectors, including financial services, banking, insurance, utilities, telecommunications, and the public sector, for designing, composing, and producing complex business-to-consumer documents. Its unique capability to integrate data from multiple sources allows for the creation of personalized communications. Recently, Open Print has been increasingly adopted for redesigning mission-critical documents to incorporate marketing campaigns, thereby generating new revenue opportunities. The UK office, established in 1999 in Bristol, serves notable clients such as Nationwide and British Telecom, who have been utilizing Sefas' solutions since the early 2000s.

Idylis S.A., established in 2008 and headquartered in Issy-les-Moulineaux, France, specializes in designing, developing, and marketing software solutions tailored for enterprise management. The company's product suite supports a range of applications including audit and accounting, financial management, documentation, e-mailing, scheduling, supply chain management, logistics, and inventory management. Additionally, Idylis offers customer support and consulting services to enhance the effectiveness of its software solutions for clients.

DSO Interactive SA designs, develops, and markets software solutions for intermediation of Internet platforms. Its products include auditing and decisional software systems for legal firms. The company also offers information technology and communication consulting services. It was formerly known as Convergence SA and changed its name to DSO Interactive in September 2004. The company was founded in 2001 and is based in Paris, France.

VoluBill S.A. is a provider of real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and based in Montbonnot Saint Martin, France, with additional offices in Europe and Asia, the company specializes in solutions for fixed, mobile, and fixed mobile convergent operators. VoluBill's product offerings include CHARGE-IT, which facilitates real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement; and CHARGE-IT Dynamic Charging Platform, which supports various charging models such as pre-pay, post-pay, and now-pay for data services.

Founded in 1998, Netasq is an information security company based in France. It has designed and markets Unified Threat Management solutions (hardware appliances based on a derivative of FreeBSD) which combine network and application firewall with embedded anti-virus, anti-spam, VPN and content filtering functionality with an integrated real-time intrusion prevention technology: the ASQ (Active Security Qualification).

Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.

METabolic EXplorer, founded in 1999 and headquartered in Saint-Beauzire, France, is a biochemistry company specializing in the development of industrial fermentation processes as sustainable alternatives to petrochemical methods. The company produces functional ingredients from natural origins for use in cosmetics, nutrition-animal health products, and biomaterials synthesis. By leveraging bacterial biochemistry, METabolic EXplorer aims to create viable, long-term solutions based on renewable resources, focusing on economic performance and competitiveness. The company continually works to enhance the efficiency of microorganisms and diversify the supply of renewable raw materials to produce essential chemical compounds with wide-ranging industrial applications.